Approximately C$90M raised to date. Well-funded to progress clinical trials and M&A strategy.
Commenced trading on NEO EXCHANGE and MJDS eligible for US listing.
Canada’s largest go-public financing round in the psychedelic sector by raising C$45M. Strategic shareholder base of round subscribed to by top US biotech funds e.g., Janus Henderson, LifeSci Ventures and RA Capital.
Deep Experience in healthcare, M&A, and capital markets.
CEO with over 30 years in the healthcare sector and has raised over US$4B in capital and has led over US$5B in M&A activity.
Successfully helped develop widely-used drugs: Allegra, Sabril, Anzemet & Vaniqa.
300 combined peer-reviewed publications by scientific leadership include work in addiction and psychedelics.
Overseen 60+ IND programs with FDA.
Acquired Boston-based pharmaceutical company ADELIA THERAPEUTICS INC.
Inked technology partnership with KERNEL to leverage breakthrough neuroimaging in upcoming clinical trials.
10 Patent Filings cover:
Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.
API Modification
Develop new APIs via selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential.
Modifications involve replacing selective hydrogens with deuterium atoms.
Optimizing unique physicochemical attributes e.g. salts, crystal forms, co-crystals, etc.
Research and Develop
Efficient delivery system that attempts to bypass the liver metabolism with a direct path to the brain providing a faster onset.
Modified-release formulations with the potential to reduce side effects and to control exposure.
Dose control through proprietary device platform.
Delivery systems may be applied to many psychedelic compounds.
Science Meets Technology
Software-based platform to gather clinical research data from psychedelic treatment.
Machine learning-based data analytics for improved patient outcomes.
Patient therapy and integration support.
This plan is suitable for the beginner IT specialist and will allow you to familiarize yourself with all the main functions of the service.
This plan is suitable for the freelancers and will allow you to familiarize yourself with all the main functions of the service.
Experience
Our relentless pursuit to commercialize these revolutionary treatments is supported by our diverse team of scientific and business experts. Our group brings the following expertise:
Development Pipeline
13 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.
Cybin is leveraging parent molecules that have shown positive early efficacy and optimizing their pharmacokinetics, bioavailability, and delivery through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.
see our programsPartnerships
see partnerships
“We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients."
Our relentless pursuit to commercialize these revolutionary treatments is supported by our diverse team of scientific and business experts. Our group brings the following expertise:
*Partnershipdevelopment program with Catalent (NYSE:CTLT). Cybin will leverage the Zydistechnology which is regarded as one of the world’s best performing ODTs thatwould allow pre-gastric delivery and prevent first pass metabolism thus potentially improving thepharmacokinetic profile of the drug.
14 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.
Cybin is leveraging parent molecules that have shown positive early efficacy and optimizing their pharmacokinetics, bioavailability, and delivery through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.
Acquired and successfully integrated Boston-based pharmaceutical company bringing immense experience in the scientific and psychedelic sectors.
Partnered with technology leader to leverage breakthrough neuroimaging hardware and software in upcoming clinical trials.
Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence
Cybin Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
“We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients."
